Current and novel immunosuppressive therapy for autoimmune hepatitis.

摘要: Corticosteroids alone or in conjunction with azathioprine is the treatment of choice patients autoimmune hepatitis (AIH) and results remission induction over 80% patients. Sustained response to therapy may result substantial regression fibrosis even advanced cases. The outcome rapid withdrawal immunosuppression disease relapse many Consequently, use 2 mg/kg/d as a sole agent maintain has been widely accepted clinical practice. Persistent severe laboratory abnormalities histologic such bridging necrosis multilobular are absolute indications for based on controlled trials, but debate exists whether all AIH need treatment. Examination liver tissue remains best method evaluating both who have little biochemical activity. Alternative strategies failed achieve "standard therapy" corticosteroids without drug toxicity include cyclosporine, tacrolimus, mycophenolate mofetil. Liver transplantation managing decompensated disease. In this review we examine current management AIH, evaluate available data pertaining novel immunosuppressive agents condition.